Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer

Mark F McCarty1

  • 1NutriGuard Research, 1051 Hermes Ave., Encinitas, CA 92024, USA. markfmccarty@gmail.com

Medical Hypotheses
|December 2, 2011
PubMed

Insights

Metformin, a diabetes drug, combats cancer stemness by increasing let-7 microRNA levels. This approach, targeting cancer stem cells, shows promise for improving cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Most tumors contain cancer cells with stem cell characteristics, driving invasive growth, metastasis, and chemoresistance.
  • Reduced levels of let-7 microRNAs are typical in cancer stem cells and may drive cancer stemness.
  • Metformin, a diabetes drug, has shown potential in cancer prevention and treatment.

Purpose of the Study:

  • To investigate metformin's effect on cancer stemness and let-7 microRNA levels.
  • To explore the mechanisms by which metformin influences cancer stem cells.
  • To identify complementary strategies for enhancing metformin's anti-cancer effects.

Main Methods:

  • Investigated metformin's impact on cancer stemness in mouse xenograft models.
  • Assessed metformin's effect on let-7a levels in cancer stem cells.
  • Proposed mechanisms involving AMPK, Lin28/Lin28A, NF-kappaB, and Myc.

Main Results:

  • Metformin opposed cancer cell stemness and potentiated chemotherapeutic control in xenograft models.
  • Metformin significantly increased let-7a levels in cancer stem cells.
  • Evidence suggests metformin's effects may be mediated by AMPK-dependent inhibition of Lin28/Lin28A.

Conclusions:

  • Metformin shows potential for reversing cancer stemness and enhancing cancer treatment.
  • Targeting Lin28/Lin28A and related pathways (NF-kappaB, Myc) could complement metformin therapy.
  • Multifocal strategies involving metformin may improve long-term control of advanced cancers.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...